Comment from Cystic Fibrosis Foundation

Summary: The Cystic Fibrosis Foundation supports the FDA's initiative to create an expedited Investigational New Drug (IND) pilot program to accelerate early-stage drug development. They recommend a staged implementation focusing on low-risk products and suggest exploring elements of the Australian Clinical Trial Notification (CTN) scheme to streamline the process.